Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Vironexis Biotherapeutics Inc.
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06533579CT.gov Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Marginal Zone Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vnx-101 (this asset) | Vironexis Biotherapeutics Inc. | P1/2 | CC · 43 |
| Etoposide | University of Miami | P2 | BBB |
| Orelabrutinib | Henan Cancer Hospital | P4 | BBB |
| Nivestim | Fred Hutchinson Cancer Center | P2 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Vincristine Sulfate | Mayo Clinic | P2 | BBB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Irinotecan | National Cancer Institute (NCI) | P2 | BB |
| Romidepsin | City of Hope Medical Center | P2 | BB |
+42 more in the Marginal Zone Lymphoma cohort
Other indications for Vnx-101
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P1/2 | CC · 45 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P1/2 | CC · 45 |
| Non-Hodgkin Lymphoma | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vnx-101 in Marginal Zone Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vnx-101-marginal-zone-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →